Teva Pharmaceutical Industries Presents Final Analysis of PEARL Study Demonstrating Sustained Effectiveness of AJOVY in Migraine Prevention at EAN 2025 Congress
The PEARL study confirms fremanezumab's long-term effectiveness and safety in migraine prevention over two years.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
